RLMD
RELMADA THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$4.12
−1.90%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$0.14
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.11
- EPS estimate
- -$0.20
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -180.1%
- Revenue beats (12Q)
- —
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.20 | -$0.11 | Beat 44.87% | — |
| May 12, 2026 | -$0.18 | -$0.22 | Miss -22.22% | — |
| Mar 19, 2026 | -$0.14 | -$0.27 | Miss -92.86% | — |
| Nov 13, 2025 | -$0.04 | -$0.30 | Miss -650.00% | — |
| Aug 7, 2025 | -$0.25 | -$0.30 | Miss -20.00% | — |
| Mar 27, 2025 | -$0.70 | -$0.62 | Beat 11.43% | — |
| Nov 7, 2024 | -$0.65 | -$0.72 | Miss -10.77% | — |
| Mar 19, 2024 | -$0.88 | -$0.84 | Beat 4.55% | — |
| May 11, 2023 | -$0.88 | -$0.87 | Beat 1.14% | — |
| Mar 23, 2023 | -$1.33 | -$1.26 | Beat 5.26% | — |
| Nov 10, 2022 | -$1.40 | -$1.31 | Beat 6.43% | — |
| Aug 11, 2022 | -$1.30 | -$1.33 | Miss -2.31% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026